Atlas FDA

THxID-BRAF assay kit

FDA premarket approval P120014/S010 · decided 2020-02-26

Approval details

PMA number
P120014
Supplement
S010
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
THxID-BRAF assay kit
Generic name
Somatic gene mutation detection system
Applicant
bioMerieux, Inc.
Date received
2020-01-31
Decision date
2020-02-26
Days to decision
26 days
Decision code
OK30
Product code
OWD
Advisory committee
Pathology
Expedited review
No
Location
Hazelwood, MO
Statement
Change of manufacturing material and manufacturer of the manufacturing material

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
VITEK REVEAL GN AST Assay and VITEK REVEAL AST System (K260160)bioMerieux, Inc.2026-07-08
VITEK 2 AST-Streptococcus Inducible Clindamycin Resistance (K260282)bioMerieux, Inc.2026-04-15
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL) (K251579)bioMerieux, Inc.2025-08-21
VITEK COMPACT PRO (K234012)bioMerieux, Inc.2025-03-14
VITEK 2 AST-Yeast Voriconazole (<= 0.03125 - >= 4 µg/mL) (K232967)bioMerieux, Inc.2024-06-12
VITEK 2 AST-Yeast Anidulafungin (<= 0.015 - >= 8 µg/mL) (K232963)bioMerieux, Inc.2024-06-07
VIDAS TBI (GFAP, UCH-L1) (K240279)bioMerieux, Inc.2024-05-01
VITEK 2 AST-Gram Positive Lefamulin (<=0.03 - >=4 µg/mL) (K234000)bioMerieux, Inc.2024-03-11